Barron Biomedical is a research-based and an application-oriented enterprise in the field of personalized cancer medicine. We support pathologists and oncologists in identifying the most suitable treatment for the individual cancer patient.
Even if our focus is the patient, we hope that our expertise in obtaining high-quality samples can one day support the medical-scientific community in two key research areas:
Subset of gene alterations (mutations, deletions, amplifications, fusions, etc.) with diagnostic, prognostic, therapeutic or predictive implications, i.e. can be used to inform clinical management of patients1.
The sequence encompassing all exons of an organism (exons are the gene regions encoding for proteins).
A target is a molecule with several properties:
Molecules with these properties are mostly members of signal pathways for proliferation or for apoptose. They can be targets for drugs, which stop the growth and spread of cancer cells. These drugs known as "targeted therapies" limit or avoid harm to normal cells.
A biomarker is a measurable biological feature that acts as an indicator for a physiological, pathological or pharmacological process in the body2.
Modern biology shows that such processes taking place in the body are driven and accompanied by changes in DNA, RNA, proteins and metabolites of the involved cells and tissues. For this reason, these molecular features can be employed as biomarkers for the aforementioned processes and therefore can convey medical predictions. For example:
Biomarkers may function as a single feature, such as a DNA-mutation, or as a group of features, such as several RNA species.